Literature DB >> 17403982

The effects of an indigenous muscarinic drug, Betel nut (Areca catechu), on the symptoms of schizophrenia: a longitudinal study in Palau, Micronesia.

Roger J Sullivan1, Sylvia Andres, Caleb Otto, Wayne Miles, Robert Kydd.   

Abstract

OBJECTIVE: This study tested the findings of a prior study indicating a therapeutic relationship between consumption of betel nut and symptoms of schizophrenia.
METHOD: The subjects were 65 outpatients with diagnoses of schizophrenia or schizoaffective disorder. Symptoms rated with the Positive and Negative Syndrome Scale were compared between high- and low-consumption betel chewers in a repeated-measures design. Movement disorders were assessed with the Abnormal Involuntary Movement Scale and Simpson-Angus Rating Scale. Global health and social functioning were assessed with the Medical Outcomes Study 12-item and 36-item Short-Form Health Surveys, respectively.
RESULTS: Male high-consumption betel chewers had significantly milder positive symptoms than low-consumption chewers over 1 year. Betel chewing was not associated with global health, social functioning, or movement disorders. Betel chewing was associated with tobacco use but not with cannabis or alcohol.
CONCLUSIONS: These findings have clinical significance in betel-chewing regions and broader implications for theory of muscarinic neurophysiology in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17403982     DOI: 10.1176/ajp.2007.164.4.670

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  9 in total

1.  The mysterious illness of dyce sombre.

Authors:  Ronald Pies; Michael H Fisher; C V Haldipur
Journal:  Innov Clin Neurosci       Date:  2012-03

2.  Specificity of familial transmission of schizophrenia psychosis spectrum and affective psychoses in the New England family study's high-risk design.

Authors:  Jill M Goldstein; Stephen L Buka; Larry J Seidman; Ming T Tsuang
Journal:  Arch Gen Psychiatry       Date:  2010-05

3.  Areca nut chewing is associated with common mental disorders: a population-based study.

Authors:  Tzu-Yu Lin; Huan-Cheng Chang; Kuang-Hung Hsu
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2017-11-15       Impact factor: 4.328

4.  Areca (betel) nut chewing practices of adults and health behaviors of their children in the Freely Associated States, Micronesia: Findings from the Children's Healthy Living (CHL) Program.

Authors:  Yvette C Paulino; Reynolette Ettienne; Rachel Novotny; Lynne R Wilkens; Moria Shomour; Cecilia Sigrah; Shelley D Remengesau; Emihner L Johnson; Julia M Alfred; Daisy F Gilmatam
Journal:  Cancer Epidemiol       Date:  2017-10       Impact factor: 2.984

5.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

Review 6.  Genetic toxicology and toxicokinetics of arecoline and related areca nut compounds: an updated review.

Authors:  Nuno G Oliveira; Daniela L Ramos; Ricardo Jorge Dinis-Oliveira
Journal:  Arch Toxicol       Date:  2020-10-24       Impact factor: 5.153

7.  Nicotinic Activity of Arecoline, the Psychoactive Element of "Betel Nuts", Suggests a Basis for Habitual Use and Anti-Inflammatory Activity.

Authors:  Roger L Papke; Nicole A Horenstein; Clare Stokes
Journal:  PLoS One       Date:  2015-10-21       Impact factor: 3.240

8.  Identifying Plant-Human Disease Associations in Biomedical Literature: A Case Study.

Authors:  Vivekanand Sharma; Wayne Law; Michael J Balick; Indra Neil Sarkar
Journal:  AMIA Jt Summits Transl Sci Proc       Date:  2016-07-19

Review 9.  Adverse Health Effects of Betel Quid and the Risk of Oral and Pharyngeal Cancers.

Authors:  Ping-Ho Chen; Qaisar Mahmood; Gian Luigi Mariottini; Tai-An Chiang; Ka-Wo Lee
Journal:  Biomed Res Int       Date:  2017-12-11       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.